Current treatment landscape for oligometastatic non-small cell lung cancer

Table 1 Main studies on stereotactic body radiotherapy for the treatment of oligometastatic non-small cell lung carcinoma

Ref.	Year	Patients (n)	Site of oligo-metastasis	N	Dose (Gy/fraction)	Systemic therapy	Median follow-up (mo)	Median PFS (mo)	Median OS (mo)
Retrospective studies
Inoue et al[27]	2010	411	Brain, lung, adrenal	< 5	48/8 (adrenal)35-60/4-8 (lung)	NA	20	3-yr PFS 20%	24
Hasselle et al[28]	2012	25	Multiple	< 5	24-70/3-20	Various	21	4.2 (all); 12 (1 met)	23 (1 met)
De Rose et al[26]	2016	60	Lung	< 5	48-60/3-8	Chemo	28	32.2 (actuarial)	32.1 (actuarial)
Single arm prospective trials
Salama et al[23]	2012	611	Multiple	< 5	24-48/3	Chemo	20.9	2-yr PFS 22%	2-yr OS 56.7%
De Ruysscher et al[20]	2012	40	Multiple	< 5	54/32	Chemo	27.7	12.1	13.5
Collen et al[29]	2014	26	Multiple	< 5	50/10	Chemo	16.4	11.2	23
Randomized phase II trials
Gomez et al[25]	2016	49	Multiple	< 3	NR	Chemo	12.4	14.2 vs 4.4	41.2 vs 17
Iyengar et al[10]	2018	29	Multiple	< 5	21-37.5/1-5	Chemo	9.6	9.7 vs 3.5	Not reached vs 17
Palma et al[11]	2019	99	Multiple	< 5	35-60/3-8	Chemo	25	12 vs 6	41 vs 28

¹Diverse primary histology including non-small cell lung carcinoma.

²Only 1patient received stereotactic body radiotherapy.

Chemo: Chemotherapy; N: Number of oligometastatic lesions per patient; NA: Not applicable; NR: Not reported; OS: Overall survival; PFS: Progression-free survival.